TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced financial results for the fiscal year ended December 31, 2019, and provided a business update.
February 11, 2020
· 7 min read